Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Dragan, Golijanin"'
Autor:
Borivoj Golijanin, Vikas Bhatt, Ali Amin, Galina Lagos, Andre De Souza, Anthony E Mega, Dragan Golijanin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/46831773eefa45e3814822c0f16bc220
Autor:
Govind Shantharam, Ali Amin, Jorge Pereira, Ohad Kott, Catrina Mueller-Leonhard, Anthony Mega, Dragan Golijanin, Boris Gershman
Publikováno v:
Current Urology, Vol 15, Iss 1, Pp 33-38 (2021)
Abstract. Background:. There are limited bladder-preserving therapeutic options for patients with high-risk non-muscle invasive bladder cancer (NMIBC) after failed Bacillus Calmette-Guérin (BCG) therapy. Salvage intravesical docetaxel therapy was de
Externí odkaz:
https://doaj.org/article/9a8982f2baa942c8b52f626ee34eb88d
Autor:
Ohad Kott, Borivoj Golijanin, Jorge F. Pereira, Alison Chambers, Alison Knasin, Christopher Tucci, Dragan Golijanin
Publikováno v:
Frontiers in Surgery, Vol 6 (2020)
Introduction: Partial nephrectomy (PN), has become the gold standard for the surgical management of small renal masses, due to excellent oncologic control with concomitant preservation of nephron units. However, data regarding the association of obes
Externí odkaz:
https://doaj.org/article/4d513bea0ef64975b4d3bc292d903863
Autor:
Matthew J. Hadfield, Andre De Souza, Dragan Golijanin, Roxanne Wood, Adam Olszewski, Sheldon L. Holder, Wafik S. El-Deiry, Rahul Aggarwal, Anthony Mega, Benedito A. Carneiro
Publikováno v:
Cancer Research. 83:CT158-CT158
Background: Molecular alterations in genes regulating homologous recombination (HR) confer sensitivity of mCRPC to poly ADP-ribose polymerase inhibitors (PARPi). Increased activation of thePI3K-AKT-mTOR pathway in mCRPC contributes to tumor progressi
Autor:
Anna Moshnikova, Borivoj Golijanin, Ali Amin, Joshua Doyle, Ohad Kott, Boris Gershman, Michael DuPont, Yujing Li, Xiongbin Lu, Donald M. Engelman, Oleg A. Andreev, Yana K. Reshetnyak, Dragan Golijanin
Publikováno v:
Front Urol
Acidity is a useful biomarker for the targeting of metabolically active cells in tumors. pH Low Insertion Peptides (pHLIPs) sense the pH at the surfaces of tumor cells and can facilitate intracellular delivery of cell-permeable and cell-impermeable c
Autor:
Borivoj Golijanin, Michael DuPont, Ali Amin, Anna Moshnikova, Ohad Kott, Yana Reshetnyak, Oleg Andreev, Dragan Golijanin
Publikováno v:
Journal of Urology. 207
Autor:
Borivoj Golijanin, Sarah Andrea, Justin Bessette, Rebecca Ortiz, Philip Caffery, Timothy O'Rourke, Christopher Tucci, Ali Amin, Dragan Golijanin
Publikováno v:
Journal of Urology. 207
Autor:
Andrew Leone, Katherine Rotker, Christi Butler, Anthony Mega, Jianhong Li, Ali Amin, Stephen F. Schiff, Gyan Pareek, Dragan Golijanin, Joseph F. Renzulli
Publikováno v:
Prostate Cancer, Vol 2015 (2015)
Purpose. Atypical small acinar proliferation (ASAP) is diagnosed in 1-2% of prostate biopsies. 30–40% of patients with ASAP may be diagnosed with prostate cancer (PCa) on repeat biopsy. Our objective was to examine the association between ASAP and
Externí odkaz:
https://doaj.org/article/d9cc5892b8e141c88e60cc0063115970
Autor:
Jorge Pereira, Boris Gershman, Catrina Mueller-Leonhard, Christopher Tucci, Zheng Zhang, Dragan Golijanin, Ali Amin, Anthony Mega, Gyan Pareek
Publikováno v:
Urology. 125:131-137
Objectives To characterize the perioperative morbidity of transurethral resection of bladder tumor (TURBT) in order to identify important determinants of both quality and cost in the delivery bladder cancer care. Methods We identified 24,100 patients
Autor:
Wafik S. El-Deiry, Taylor Arnoff, Benedito A. Carneiro, Andre DeSouza, Ali Amin, Howard Safran, Elisabeth I. Heath, Monika Joshi, Dragan Golijanin, Sheldon L. Holder, Anthony E. Mega, Moh'd M. Khushman, Sourat Darabi, Emmanuel S. Antonarakis, Anwaar Saeed, Emil Lou, Alex Farrell, Jun Yin, Elizabeth R. Plimack, Rana R. McKay
Publikováno v:
Journal of Clinical Oncology. 40:4571-4571
4571 Background: p53 target and cell cycle inhibitor CDKN1A/p21(WAF1) was initially not found to be mutated in cancer. TCGA analysis identified CDKN1A mutations are present but rare with frequencies of < 1%, but enrich in bladder cancer (̃8%). Trunc